Literature DB >> 17934731

Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines.

Rosa Méndez1, Teresa Rodríguez, Ana Del Campo, Eva Monge, Isabel Maleno, Natalia Aptsiauri, Pilar Jiménez, Susana Pedrinaci, Graham Pawelec, Francisco Ruiz-Cabello, Federico Garrido.   

Abstract

BACKGROUND: Altered HLA class I cell surface expression is one of the major mechanisms by which tumor cells escape from T lymphocytes. Immunohistochemistry-defined phenotypes of lost HLA class I expression have been described in human solid tumors, nut less information is available on melanoma cell lines.
OBJECTIVES: To describe the frequency and distribution of different types of HLA class I antigen alterations in 91 melanoma cell lines from the European Searchable Tumour Cell and Databank (ESTDAB).
METHODS: The HLA class I expression was assessed by flow cytometry and HLA genotyping.
RESULTS: We found various types of HLA class I cell surface alterations in about 67% of the melanoma cell lines. These alterations range from total to selective HLA class I loss due to loss of heterozygosity (LOH), haplotype loss, beta2-microglobulin gene mutation, and/or total or selective down-regulation of HLA class I molecules. The most frequently observed phenotype is down-regulation of HLA-B locus that was reversible after treatment with IFN -gamma.
CONCLUSIONS: In general, HLA class I alterations in the majority of the cells analyzed were of regulatory nature and could be restored by IFN-gamma. Analysis of the frequency of distinct HLA class I altered phenotypes in these melanoma cell lines revealed specific differences compared to other types of tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934731     DOI: 10.1007/s00262-007-0411-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.

Authors:  Hans Klingemann; Carrie Grodman; Elliott Cutler; Marvin Duque; Diane Kadidlo; Andreas K Klein; Kellie A Sprague; Kenneth B Miller; Raymond L Comenzo; Tarun Kewalramani; Neng Yu; Richard A Van Etten; David H McKenna
Journal:  Transfusion       Date:  2012-06-28       Impact factor: 3.157

2.  Analysis of HLA-ABC locus-specific transcription in normal tissues.

Authors:  Ana Belén García-Ruano; Rosa Méndez; José María Romero; Teresa Cabrera; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Immunogenetics       Date:  2010-09-15       Impact factor: 2.846

Review 3.  Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.

Authors:  Nagendra Natarajan; Sucheta Telang; Donald Miller; Jason Chesney
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

4.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

5.  Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.

Authors:  Rafael Carretero; José M Romero; Francisco Ruiz-Cabello; Isabel Maleno; Felix Rodriguez; Francisco M Camacho; Luis M Real; Federico Garrido; Teresa Cabrera
Journal:  Immunogenetics       Date:  2008-06-11       Impact factor: 2.846

6.  Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies.

Authors:  Ji Qian; Hongliang Liu; Sheng Wei; Zhensheng Liu; Yangkai Li; Li-E Wang; Wei V Chen; Christopher I Amos; Jeffrey E Lee; Mark M Iles; Matthew H Law; Anne E Cust; Jennifer H Barrett; Grant W Montgomery; John Taylor; Julia A Newton Bishop; Stuart Macgregor; D Timothy Bishop; Graham J Mann; Nicholas K Hayward; Qingyi Wei
Journal:  Pigment Cell Melanoma Res       Date:  2013-03-27       Impact factor: 4.693

7.  Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody.

Authors:  G Richtig; E Ramelyte; L Koch; H Greinix; S Ferrone; R Dummer; E Richtig
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-05-26       Impact factor: 6.166

8.  IRF5 gene polymorphisms in melanoma.

Authors:  Lorenzo Uccellini; Valeria De Giorgi; Yingdong Zhao; Barbara Tumaini; Narnygerel Erdenebileg; Mark E Dudley; Sara Tomei; Davide Bedognetti; Maria Libera Ascierto; Qiuzhen Liu; Richard Simon; Leah Kottyan; Kenneth M Kaufman; John B Harley; Ena Wang; Steven A Rosenberg; Francesco M Marincola
Journal:  J Transl Med       Date:  2012-08-21       Impact factor: 5.531

9.  Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.

Authors:  Mohammad Hojjat-Farsangi; Fatemeh Ghaemimanesh; Amir Hossein Daneshmanesh; Ali-Ahmad Bayat; Jafar Mahmoudian; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Hakan Mellstedt
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.